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Summary
 Segmentectomy and sentinel lymph node biopsy is a golden standard for early breast cancer (clinical and radiological 
cT1-2, c N0). Recently, superparamagnetic iron oxide (SPIO) nanoparticle tracer has been introduced enabling intraopera-
tive tracer injection. We prospectively recorded data on tumor histology, marked lymph nodes and their fi nal histology and 
patient characteristics for early breast cancer patients who underwent breast conservative surgery. At 128 female breast 
cancer patients underwent sentinel lymph node biopsy by SentiMag. Three patients were excluded from further analysis 
because the postoperative pathology report was ductal carcinoma in situ (DCIS). The identifi cation rate was 95.2 % (119 of 
125). Of the 19.2 % (24 of 125) patients with lymph node involvement, 1.6% (2 of 125) had micrometastasis, and 1 % (1 of 125) 
had single tumor cells within the sentinel, l at least a micrometastasis. Of 30 positive lymph nodes removed, 24 (80 %) were 
true sentinel nodes. The average lymph node retrieval rate was 2.3 nodes per patient. SentiMag’s performance was compa-
rable to published data and to standard sentinel with blue patent die and/or technetium. The benefi t of easier application 
and logistics is a great advantage. 
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SENTIMAG BIOPSIJA LIMFNOG ČVORA STRAŽARA U KONZERVATIVNOJ KIRURGIJI DOJKE 
– PRELIMINARNI REZULTATI
Sažetak
  Segmentektomija i biopsija limfnog čvora stražara zlatni su standard za kirurško liječenje ranog raka dojke (klinički 
i radiološki cT1-2,c N0). Čestice superparamagnetskog željeznog oksida (superparamagnetic iron oxide, SPIO) od nedavno se 
koriste kao unutaroperacijski nanočestični obilježivač. Prospektivno smo bilježili demografske podatke o bolesnicama, hi-
stologiju tumora te označenih i neoznačenih limfnih čvorova. U 128 bolesnica učinjena je biopsija limfnog čvora stražara u 
aksili detektorom SentiMag. Tri bolesnice su isključene, jer je konačan patohistoloski nalaz bio carcinoma ductale in situ 
(DCIS). Limfni čvor je pronađen u 119 od 125 bolesnica (95.2%), pozitivne limfne čvorove su imale 24 (19.2%), makrometa-
saze 2 (1.6%) i mikrometastaze 1 bolesnica (0.08%). Od 30 pozitivnih odstranjenih limfnih čvorava, obilježenih je bilo 24 (80 
%). Prosječno su po bolesnici izvađena 2.3 limfna čvora. Mogućnost otkrivanja limfnog čvora stražara SentiMagom uspore-
diva je s dosad objavljenim podatcima i zlatnim standardom. Prednosti metode su lakše rukovanje i minimalna logistika. 
KLJUČNE RIJEČI: SentiMag, Sienna+®, superparamagnetski željezni oksid, rani rak dojke
INTRODUCTION
Sentinel node biopsy is the standard of care 
for staging of early breast cancer (1). Sentinel lymph 
node biopsy is accepted as the fi nal surgical proce-
dure in the axilla when the sentinel node (SN) is 
proven negative and sometime even in the pres-
ence of metastases (2). Moreover, neoadjuvant 
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breast cancer treatment indications require more 
sentinel lymph node biopsies (3). At our Institu-
tion we surgically treat over 800 newly diagnosed 
breast cancer patients annually. Due to well orga-
nized One Day clinic a signifi cant number of pa-
tients is diagnosed with early breast cancer (4). 
Nuclear medicine division is dislocated and this 
proved to complicate the standard isotope based 
sentinel lymph node biopsy procedure. Therefore, 
we welcomed the emergence of superparamag-
netic iron oxyde (SPIO) nanoparticle tracer in clin-
ical use backed with The SentiMag Multicentre 
Trial (5), The Nordic SentiMag Trial (6) and The 
Central European SentiMag study (7). In this pa-
per, we analyzed our initial experience with the 
method.
METHODS
Early breast cancer patients are defi ned as 
T1-2 axillary lymph node negative tumors on imag-
ing (either ultrasound or magnetic resonance imag-
ing), with primary tumor confi rmed by cytology or 
core biopsy. Exclusion criteria were prior breast 
surgery or irradiation of breast and/or axillary re-
gion. Patients hypersensitive to iron products or 
dextrate were excluded as well as patients suff ering 
of diseases with iron overload.  Sienna+® suspen-
sion (2 ml) is applied subcutaneously under nipple 
areola complex followed by 5 minutes of massage 
to the injection area. We performed the entire se-
quence when patient is already under anesthesia 
due to potential discomfort. There is a 20 minutes 
Figure 2. Detection of SIOS positive node with the probe (a) and verifi cation of the extracted node (b)
Figure 1. Application of Sienna+® suspension (a) and 5 minutes massage of the area (b). 
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waiting time prior to breast lesion excision. Senti-
Mag device is then applied transcutaneous to hint 
the sentinel node location. Axillary skin incision is 
then made and the lymph node is tracked by the 
probe signals. When the sentinel node is excised 
and confi rmed with the probe signal, the axilla is 
also checked for additional lymph nodes.The high-
est displayed signal was recorded for each extract-
ed and confi rmed sentinel node. The breast tumor 
tissue and the sentinel nodes were then analyzed 
on Pathology in standard fashion.
RESULTS
Hundred and twenty eight female patients 
were treated with breast conservative treatment 
consisting of segmentectomy and SPIO tracer axil-
lary sentinel lymph node biopsy. Three patients 
were excluded from the analysis as the fi nal pa-
thology confi rmed ductal carcinoma in situ (DCIS) 
without invasive components.Total of 294 lymph 
nodes were harvested, out of which 30 were posi-
tive and 24 were detected by SPIO tracer (19%). 
On average, 2.336 nodes were extirpated. The Sen-
tiMag count was 2664 on average, ranging from 
140-10000.
Preoperative diagnosis was made by cytolo-
gy in 68.0% (87 of 128), in 11.7% (15 out of 128) by 
core biopsy.
We compared the lymph node positivity ac-
cording to localization, but the number of tumors 
at each localization was not suffi  cient for the anal-
ysis. Finally, 24 out of 24 identifi ed lymph nodes 
were positive, to 24 SentiMag detected additional 
6 patients positive on pathology).
DISCUSSION
Current standard for sentinel lymph node bi-
opsy remains technetium 99m radioisotope and 
patent blue die tracers. Their application requires 
nuclear medicine department which makes this 
method unavailable to great number of surgical 
departments dealing with early breast cancer. The 
logistical simplifi cation with SPIO tracer and Sen-
tiMag probe was the most important reason for 
adopting the technique at our institution. The Sen-
tiMag Multicentre Trial (5), The Nordic SentiMag 
Trial (6) and The Central European SentiMag (7) 
study designed as non-inferiority study on 150 pa-
tients showed a detection rate of 97,3% (146/150) 
for (99m)Tc and 98% (147/150) for Sienna+® (8). 
The French SentiMag feasibility trial confi rmed the 
non-inferiority on 108 patients. Sentinel lymph 
node (SLN) identifi cation rate was 98.1% (93.5-
99.8) for both methods, 97.2% for Sienna+® and 
95.4% for (99m) Tc and blue die. A mean of 2.1 sen-
tinel lymph nodes per patient was removed (9). 
Italian trial confi rmed these fi ndings with detec-
tion rates per patient for (99m)Tc was 99% and 
97,9% for SentiMag based on 193 women analyzed 
in the study (10). Similar study was performed in 
Spain on 181 patients. Detection rates were 97.8% 
for SentiMag and 98.3% for (99m) Tc (concordance 
rate 99.4%). The study also compared ex-vivo de-
tection rates (97.8%, SentiMag and 98.3% (99m)Tc); 
concordance rate 99.4%), transcutaneous and in-
traoperative detection rates (95.5% vs 97.2%, and 
97.2% vs 97.8% for SentiMag and (99m)Tc; concor-
dance rates > 97%) and node level detection rates 
Figure 3. Localization of primary breast lesion. Overlapping 
 lesions denote either tumors between quadrants or multiple 
 tumors.
Table 1.
SENTINEL LYMPH NODE POSITIVITY IN CORRELATION 






pT1a 4 (3,2) 0 9 (3.08)
pT1b 27 (21,6) 1 (3,7) 75 (25.68)
pT1c 65 (52,0) 16 (24,6) 153 (52.4)
pT2 29 (23,2) 7 (24,1) 55 (18.84)
All stages 125 (100) 24 (19,2) 292 (100)
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intraoperatively and ex-vivo (92.5% vs 89.3% and 
91.0% vs 86.3% for SentiMag and (99m)Tc) (11).
In our preliminary fi ndings, the sensitivity 
was comparable to published data. Due to at least 
one additional lymph node harvested during the 
procedure we were able to detected additional 6 
positive lymph nodes. Nevertheless, during the in-
troduction of the method we observed inconsistent 
probe signals in elderly (patient born in 1929 had 
the minimal signal for a positive node 140), we had 
inconsistent data for patients with high BMI, diabe-
tes, vascular diseases or smokers, therefore we 
could not reach a valid conclusion on these biases. 
The BMI issue was more carefully studied than the 
others, since the depth sensitivity of the probe is 
currently inferior to radioisotope based system 
(12). Experimental porcine model suggested 59 nm 
superparamagnetic iron oxide tracer as optimal 
due to speed and selectivity of node uptake (13). To 
further increase the sensitivity the same group 
achieved larger number of nodes tracked with in-
creased volumes of tracers and longer waiting time 
to incision, up to 60 minutes (14).
As for the cost eff ectiveness, the standard 
method and SentiMag are comparable, but partial 
axillary lymph node dissection, spares the nerves 
and has the same rate of lymphedema as SLNB, 
harvests false negative SLNBs and is less time con-
suming.
Despite above mentioned shortcomings of 
the superparamagnetic tracer detection method, a 
meta-analysis by MD Anderson group showed 
once again a no inferiority of Sienna+® mapping 
agent to current standard on 1683 lymph nodes 
from 804 patients who participated in fi ve trials. 
Their conclusion will bring this method closer to 
becoming the standard (15). 
CONCLUSION
Based on these data we adopted the tech-
nique and have reached similar conclusions to 
those already published. These are our prelimi-
nary experiences and the more in depth analysis 
of BMI, age, localization and pathology fi ndings 
will be conducted in near future.
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